Cello Health BioConsulting
  • menu
  • Home
  • About us
    • Why We’re Different
    • Our Team
    • Mission, Vision & Values
  • Capabilities
    • Common Client Dilemmas
    • Opportunity Assessments
    • Opportunity Search and Evaluation
    • Portfolio and Platform Strategy
    • Business Development & Partnering Strategy
    • Market Access Strategy
    • Early Stage Strategy
  • Our Insights
    • News
    • Presentations
    • Testimonials
    • Events
  • Careers
    • Current Opportunities
    • A Day in the Life
    • Our Culture
A Joint Research Collaboration With A Global Pharma Company On Protein Degradation Platform

A Joint Research Collaboration With A Global Pharma Company On Protein Degradation Platform

View The Article +
Pfizer hits the gas pedal in the mRNA flu vaccine development race, inking a $425M investment pact with BioNTech

Pfizer hits the gas pedal in the mRNA flu vaccine development race, inking a $425M investment pact with BioNTech

View Article +
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome

View Article +
Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank

Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank

View Article +
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Third Review of Unblinded Data

The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Third Review of Unblinded Data

View Article +
MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn’s Disease

MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn’s Disease

View Article +
Nanobiotix Announces Positive Phase Ii/iii Topline Data In Soft Tissue Sarcoma With Nbtxr3

Nanobiotix Announces Positive Phase Ii/iii Topline Data In Soft Tissue Sarcoma With Nbtxr3

View Article +
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

View Article +
Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

View Article +
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

View Article +
  2. ←
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. →

Search

Elsewhere

Let’s work together

Contact us

  • Cello Health BioConsulting
  • 25-B Hanover Road
  • Suite 320
  • Florham Park, NJ
  • 07932
  • USA
  • +1 973 292 5001
  •  
  • Part of Cello Health plc

    Follow us

    Cello Health BioConsulting

    ©2020 Defined Health, now known as Cello Health BioConsulting | Privacy policy.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Defined Health, now known as Cello Health BioConsulting
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!